MedTrace Logo

Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

NCT02836847 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2018-05-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the feasibility, efficacy and safety of target therapy according to genomic and proteomic profiling combined with GEMOX in advanced or recurrent extrahepatic cholangiocarcinoma and gallbladder carcinoma.

Conditions

  • Cholangiocarcinoma of the Extrahepatic Bile Duct
  • Gallbladder Cancer

Interventions

PROCEDURE

biological test

mutation and signal pathway activation status analysis

DRUG

GEMOX

Conventional chemotherapy:gemcitabine and oxaliplatin

DRUG

Cetuximab

DRUG

Trastuzumab

DRUG

Gefitinib

DRUG

Lapatinib

DRUG

Everolimus

DRUG

Sorafenib

DRUG

Crizotinib

Sponsors & Collaborators

  • Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

    collaborator OTHER

  • Ruijin Hospital

    collaborator OTHER

  • RenJi Hospital

    collaborator OTHER

  • Eastern Hepatobiliary Surgery Hospital

    collaborator OTHER

  • Huashan Hospital

    collaborator OTHER

  • Shanghai Jiao Tong University School of Medicine

    lead OTHER

Principal Investigators

  • liu yingbin, PHD · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2019-12-31
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02836847 on ClinicalTrials.gov